Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | CA1 | P00915 | 6/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719256 | 1.00 | LMNA (0.52) | LMNAMAPTSLC15A1CYP2D6MAPK1 | |
| SCHEMBL6447396 | 1.00 | LMNA (0.52) | LMNAMAPTSLC15A1CYP2D6MAPK1 | |
| SCHEMBL7758366 | 0.91 | LMNA (0.51) | LMNAMAPTSLC15A1CYP2D6MAPK1 | |
| SCHEMBL716770 | 0.90 | LMNA (0.54) | LMNAMAPTCYP2D6MAPK1CA2 | |
| SCHEMBL1670578 | 0.90 | LMNA (0.54) | LMNAMAPTCYP2D6MAPK1CA2 | |
| SCHEMBL719791 | 0.90 | LMNA (0.54) | LMNAMAPTCYP2D6MAPK1CA2 | |
| SCHEMBL1287362 | 0.89 | LMNA (0.49) | LMNAMAPTSLC15A1CYP2D6MAPK1 | |
| SCHEMBL5917169 | 0.89 | LMNA (0.49) | LMNAMAPTSLC15A1CYP2D6MAPK1 | |
| SCHEMBL1287363 | 0.89 | LMNA (0.49) | LMNAMAPTSLC15A1CYP2D6MAPK1 | |
| SCHEMBL7759042 | 0.87 | LMNA (0.49) | LMNAMAPTCYP2D6MAPK1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108079806-B | Polyamide semipermeable membrane, preparation method and application thereof | 浙江大学 | 2020-09-08 | — | — | CN | claimed |
| CN-108079806-A | A kind of polyamide semi-permeable membrane, preparation method and applications | 浙江大学 | 2018-05-29 | — | — | CN | claimed |
| EP-0985658-B1 | PROCESS FOR PRODUCING L-VALINE BENZYL ESTER P-TOLUENESULFONATE | SUMIKA FINE CHEMICALS CO LTD (JP) | 2004-05-12 | — | — | EP | claimed |
| EP-0985658-A1 | PROCESS FOR PRODUCING L-VALINE BENZYL ESTER P-TOLUENESULFONATE | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2000-03-15 | — | — | EP | claimed |
| CN-119799303-A | Solid surfactant and preparation method and application thereof | 中国石油化工股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20240002436-A1 | RESPIRATORY TREATMENTS | HOFSETH BIOCARE ASA (NO) | 2024-01-04 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-4247165-A1 | RESPIRATORY TREATMENTS | Hofseth Biocare ASA (NO) | 2023-09-27 | — | — | EP | disclosed |
| US-20230255922-A1 | TREPROSTINIL PRODRUGS | UNITED THERAPEUTICS CORPORATION (US) | 2023-08-17 | — | — | US | disclosed |
| US-11672775-B2 | Treprostinil prodrugs | UNITED THERAPEUTICS CORPORATION (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| US-5023237-A | Using oligopeptide containing glycine, histidine, and lysine | PROCYTE CORPORATION (US) | 1991-06-11 | — | — | US | disclosed |
| WO-1991007431-A1 | METAL-PEPTIDE COMPOSITIONS AND METHODS FOR STIMULATING HAIR GROWTH | PROCYTE CORPORATION (US) | 1991-05-30 | — | — | WO | disclosed |
| WO-1991005797-A1 | METHODS AND COMPOSITIONS FOR HEALING BONE | PROCYTE CORPORATION (US) | 1991-05-02 | — | — | WO | disclosed |
| EP-0423358-A1 | POSTOSTATIN AND RELATED COMPOUND THEREOF, OR THEIR SALTS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1991-04-24 | — | — | EP | disclosed |
| WO-1991003488-A1 | METHODS AND COMPOSITIONS FOR HEALING ULCERS | PROCYTE CORPORATION (US) | 1991-03-21 | — | — | WO | disclosed |
| EP-0408973-A1 | Antiherpes pentapeptides | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-01-23 | — | — | EP | disclosed |
| EP-0402646-A1 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1990-12-19 | — | — | EP | disclosed |
| EP-0317573-A1 | ANTIPYRETIC AND ANTI-INFLAMMATORY PEPTIDES. | UNIV TEXAS (US) | 1989-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002436-A1 | RESPIRATORY TREATMENTS | TSLP, MCOLN3, MCOLN1 | LMNA 1425/4885MAPT 3624/4885SLC15A1 3616/4885 |
| US-11672775-B2 | Treprostinil prodrugs | TYMP, TK1, DCTPP1 | LMNA 3503/4885MAPT 3076/4885SLC15A1 1299/4885 |
| US-20230255922-A1 | TREPROSTINIL PRODRUGS | TYMP, TK1, DCTPP1 | LMNA 3503/4885MAPT 3076/4885SLC15A1 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.